Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 1.0500 |
Strike | 350.00 |
Expiry date | 2024-07-19 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 89 |
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
Wall Street's main indexes were set to open higher on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen on upbeat corporate updates added support. The Labor Department report showed U.S. nonfarm payrolls increased by 175,000 jobs in April, compared with expectations for an increase of 243,000, according to economists polled by Reuters.